

Dana V Rizk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5687056/publications.pdf>

Version: 2024-02-01

52
papers

1,975
citations

257357

24
h-index

254106

43
g-index

52
all docs

52
docs citations

52
times ranked

2563
citing authors

#	ARTICLE	IF	CITATIONS
1	IgA vasculitis with nephritis: update of pathogenesis with clinical implications. <i>Pediatric Nephrology</i> , 2022, 37, 719-733.	0.9	35
2	Lactated Ringer's solution and risk of hyperkalemia in patients with reduced kidney function. <i>American Journal of the Medical Sciences</i> , 2022, 364, 433-443.	0.4	2
3	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. <i>Journal of Clinical Medicine</i> , 2022, 11, 2810.	1.0	15
4	The Forgotten Cost of Nephrotic Syndrome to Patients and Caregivers in the United States. <i>Kidney360</i> , 2022, 3, 991-992.	0.9	0
5	Cytokines and Production of Aberrantly O-Glycosylated IgA1, the Main Autoantigen in IgA Nephropathy. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 301-315.	0.5	4
6	IgA Nephropathy: An Interesting Autoimmune Kidney Disease. <i>American Journal of the Medical Sciences</i> , 2021, 361, 176-194.	0.4	91
7	The mystery of cherry red ultrafiltrate in continuous renal replacement therapy. <i>Kidney International</i> , 2021, 99, 270.	2.6	0
8	An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2493.	1.0	31
9	Prognostic value of silent myocardial infarction in patients with chronic kidney disease after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, , .	2.6	3
10	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.4	2
11	Unusual Cause for Continuous Renal Replacement Therapy Filter Clotting. <i>Kidney360</i> , 2020, 1, 225-226.	0.9	3
12	Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2019, 9, 316-325.	0.7	6
13	Second-Chance Placement of Hemodialysis Patients After Involuntary Discharge for Disruptive Behavior. <i>American Journal of Kidney Diseases</i> , 2019, 74, 544-548.	2.1	3
14	Description of 5 Novel SLC34A3/NPT2c Mutations Causing Hereditary Hypophosphatemic Rickets With Hypercalciuria. <i>Kidney International Reports</i> , 2019, 4, 1179-1186.	0.4	14
15	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 36-46.	13.9	324
16	Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2017-2026.	3.0	72
17	Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.	2.6	38
18	A Novel Fluorescent Clinical Method to Rapidly Quantify Plasma Volume. <i>CardioRenal Medicine</i> , 2019, 9, 168-179.	0.7	5

#	ARTICLE	IF	CITATIONS
19	The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. <i>Frontiers in Immunology</i> , 2019, 10, 504.	2.2	100
20	Confidence in Women's Health: A Cross Border Survey of Adult Nephrologists. <i>Journal of Clinical Medicine</i> , 2019, 8, 176.	1.0	27
21	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
22	Renal Complications in Pregnancy Preceding Glomerulonephropathy Diagnosis. <i>Kidney International Reports</i> , 2019, 4, 159-162.	0.4	12
23	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
24	FP110A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i14-i14.	0.4	2
25	Secondary IgA nephropathy. <i>Kidney International</i> , 2018, 94, 674-681.	2.6	79
26	A Novel Method for Rapid Bedside Measurement of GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1609-1613.	3.0	50
27	Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients. <i>BioTechniques</i> , 2018, 65, 71-77.	0.8	5
28	Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. <i>PLoS ONE</i> , 2018, 13, e0190967.	1.1	56
29	Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1998-2008.	3.3	16
30	Prognostic value of silent myocardial infarction in patients with chronic kidney disease being evaluated for kidney transplantation. <i>International Journal of Cardiology</i> , 2017, 249, 377-382.	0.8	9
31	The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. <i>Frontiers in Immunology</i> , 2016, 7, 117.	2.2	123
32	Migrated intra-jejunal peritoneal dialysis catheter. <i>Kidney International</i> , 2015, 88, 1457.	2.6	0
33	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). <i>Nephron</i> , 2015, 130, 159-168.	0.9	49
34	Screening for Coronary Artery Disease in Kidney Transplant Candidates. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 297-300.	1.4	8
35	New Insights into the Pathogenesis of IgA Nephropathy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 8-18.	1.2	54
36	Oral Anticoagulants and Risk of Nephropathy. <i>Drug Safety</i> , 2015, 38, 527-533.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Polycystic and Other Cystic Kidney Diseases. , 2014, , 362-370.		0
38	The Interdisciplinary Team: The Whole Is Larger Than the Parts. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 333-337.	0.6	14
39	Dietary Patterns and Risk of Death and Progression to ESRD in Individuals With CKD: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2014, 64, 204-213.	2.1	125
40	Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. <i>International Journal of Health Geographics</i> , 2013, 12, 17.	1.2	17
41	Renovascular Hypertension Associated With Pseudoaneurysm Following Blunt Trauma. <i>American Journal of Kidney Diseases</i> , 2013, 62, 839-843.	2.1	5
42	Association Between Urinary Albumin Excretion and Coronary Heart Disease in Black vs White Adults. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 706.	3.8	38
43	Cardiovascular Risk Factors in CKD Associate with Both ESRD and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1159-1165.	3.0	76
44	Cardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Vascular Health and Risk Management</i> , 2013, 9, 47.	1.0	5
45	Racial differences in albuminuria, kidney function, and risk of stroke. <i>Neurology</i> , 2012, 79, 1686-1692.	1.5	36
46	Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3482-3488.	0.4	19
47	Kidney Disease Education One Year After the Medicare Improvement of Patients and Providers Act: A Survey of US Nephrology Practices. <i>American Journal of Kidney Diseases</i> , 2012, 59, 892-894.	2.1	12
48	Warfarin-related nephropathy: another newly recognized complication of an old drug. <i>Kidney International</i> , 2011, 80, 131-133.	2.6	24
49	Age-Specific Association of Reduced Estimated Glomerular Filtration Rate and Albuminuria with All-Cause Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2200-2207.	2.2	67
50	Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients not yet on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 560-566.	2.2	63
51	Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. <i>Pediatric Nephrology</i> , 2008, 23, 1029-1036.	0.9	27
52	Cystic and inherited kidney diseases. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1305-1317.	2.1	73